Chengda Biotech said at the 2026 semi-annual results briefing held on September 22 that the company will further cultivate existing vaccine products, continue to expand domestic and foreign market channels, and consolidate the operating foundation of its main business. At the same time, the company is promoting the production and sale of new products such as human diploid vaccine and influenza vaccine in an orderly manner, which is expected to have a positive impact on revenue and profits in the future. In terms of the second growth curve, the company actively lays out the field of biomedical innovation, and short-term R&D investment may have a certain impact on current expenses. In the medium to long term, it will further strengthen its core competitive advantage, enhance operational resilience and profitability, and provide strong support for the steady growth of the company's future performance.

Chengda Biotech said at the 2026 semi-annual results briefing held on September 22 that the company will further cultivate existing vaccine products, continue to expand domestic and foreign market channels, and consolidate the operating foundation of its main business. At the same time, the company is promoting the production and sale of new products such as human diploid vaccine and influenza vaccine in an orderly manner, which is expected to have a positive impact on revenue and profits in the future. In terms of the second growth curve, the company actively lays out the field of biomedical innovation, and short-term R&D investment may have a certain impact on current expenses. In the medium to long term, it will further strengthen its core competitive advantage, enhance operational resilience and profitability, and provide strong support for the steady growth of the company's future performance.